- Access is both an execution and a pricing challenge. Payers are tightening UM, PA, site-of-care controls, and affordability scrutiny, so brands need stronger pull-through systems, not just sharper access strategy.
- Direct-to-Patient (DTP) is becoming a serious commercialization pathway, driven by payer friction, high deductibles, LOE pressure, and patient demand for simpler access.
- AI’s near-term value is in reducing access friction. The strongest use cases are PA automation, benefits verification, workflow orchestration, and patient support optimization, not abstract AI hype.
- Patient support is shifting from hub enrolment to connected care. Asembia reinforced that first script is not enough; brands need digital plus human support that helps patients start, stay, and persist on therapy.
- Cost clarity is becoming a commercialization advantage. Upfront Out-of-Pocket visibility and clearer affordability pathways can reduce abandonment and build confidence at the point of prescribing.
.png?width=1080&height=1080&name=About%20the%20conference%20-%20square%201080%20x%201080%20(3).png)
.png?width=612&height=553&name=Eric%20Daly%20(2).png)
Eric Daly
EVP, Client Growth
Alexander Levine
SVP, Oncology Business Lead
Jasmine Singh
EVP, Medical Strategy - Growth and Innovation
Eric Daly
EVP, Client Growth
Eric has 25 years of healthcare marketing experience that spans therapeutic areas from primary care and vaccine marketing to rare disease and oncology/hematology.
His experience includes years spent in immunology on Enbrel, Orencia, and Otezla. He’s worked across all channels to create behavior change among HCPs, consumers, payers, and organized customers. He’s also spent time on both the agency and client side, including leading omnichannel marketing for 4 multiple brands while at Bristol Myers Squibb—inclusive of Orencia and Opdivo. His DTC experience spans household name brands like Spiriva, Jardiance, Enbrel, and many others.
Given his experience in immunology and oncology, Eric also has significant experience marketing multi-indication brands and portfolios with customer overlap.
Alexander Levine
SVP, Oncology Business Lead
With over two decades in the industry and deep oncology expertise, Alex has led commercialization for leading brands, including Enhertu, Padcev, Avastin, Rituxan, and Venclexta. He has also worked across other therapeutic areas, such as diabetes and ophthalmology, but his passion lies in oncology. A proud New Yorker and University of Wisconsin–Madison grad, Alex enjoys spending time with his wife and daughters and cheering on the Badgers and his NY teams.
Jasmine Singh
EVP, Medical Strategy - Growth and Innovation
As a licensed clinical pharmacist and MBA in Pharmaceutical Marketing with over 20 years of experience in healthcare, Jasmine not only has an unparalleled level of medical and marketing expertise, she also brings passion, an analytical approach, and deep strategic thinking to the table. She’s helped guide high-profile brands through all phases of drug development and life-cycle management, including launching new products, new indications for existing products, and repositioning mature products to secure market share. As a clinical pharmacist, Jasmine brings real-world insight across disease states and patient types to ensure relevance and credibility in the dissemination of data. Prior to working at healthcare advertising firms, Jasmine worked at Pfizer in regulatory affairs, Sanofi-Aventis in medical affairs across the diabetes portfolio, and Johnson & Johnson in medical affairs across the oncology portfolio. Jasmine’s category experience includes oncology, cardiology, immunology, pulmonology, neurology, and endocrinology.
Emerging Trends: Time Toxicity in Oncology
Time toxicity, the cumulative time burden of cancer treatment, is a critical yet under-recognized factor that can significantly impact patient and care partner quality of life. Explore why addressing it can unlock better outcomes, equity, and a positive brand experience.
.png?width=605&height=738&name=The%20New%20Frontier%20of%20Cancer%20Care-%20Six%20Forces%20Reshaping%20Oncology%20(1).png)
Cancer’s Rare Evolution: Why Oncology Is Borrowing from Rare Disease Playbooks
Oncology is looking more and more like a rare disease in its treatment, with a shift towards hyper-personalized care and deploying digital tools that empower patients, advocates, and care partners. Check out how Klick is leading this transformation with precision strategies and integrated engagement expertise to reshape cancer care. Read more
Understanding the Unspoken Burden of Time Toxicity
In this interview, Klick Health’s Jasmine Singh sits down with Dr. Rahul Banerjee from Fred Hutchinson Cancer Institute to discuss the concept of “Time Toxicity” in cancer care. They explore how the extensive hours patients spend attending medical appointments, undergoing tests, and managing medications impact treatment decisions, quality of life, and patient outcomes. Dr. Banerjee also highlights how clinical practice and industry standards can evolve to better prioritize patient-centered care. Read more
Case Study: Co-Creating Value: How Iterative Payer Engagement Drove a Smarter Oncology Launch
This case study highlights how an insight-driven strategic advisory initiative enabled the launch of a next-generation oncology therapy with faster alignment, stronger access readiness, and more resonant, value-driven messaging. Read more